Autoimmune hemolytic anemia primary prevention: Difference between revisions
Shyam Patel (talk | contribs) |
Shyam Patel (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
{{Autoimmune hemolytic anemia}} | {{Autoimmune hemolytic anemia}} | ||
{{CMG}} {{shyam}} | {{CMG}} {{shyam}} | ||
==Overview== | ==Overview== | ||
Revision as of 23:44, 23 April 2018
|
Autoimmune hemolytic anemia Microchapters |
|
Differentiating Autoimmune hemolytic anemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune hemolytic anemia primary prevention On the Web |
|
American Roentgen Ray Society Images of Autoimmune hemolytic anemia primary prevention |
|
Directions to Hospitals Treating Autoimmune hemolytic anemia |
|
Risk calculators and risk factors for Autoimmune hemolytic anemia primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Overview
The primary prevention strategies for autoimmune hemolytic anemia include avoidance of exposure to precipitants.
Primary Prevention
The primary prevention strategies for autoimmune hemolytic anemia include avoidance of exposure to infectious agents or medications that are known to be associated with autoimmune hemolytic anemia. For example, avoidance of Mycoplasma via routine hand hygiene and avoidance of sick contacts is a primary prevention strategy.[1]
References
- ↑ Zanella A, Barcellini W (2014). "Treatment of autoimmune hemolytic anemias". Haematologica. 99 (10): 1547–54. doi:10.3324/haematol.2014.114561. PMC 4181250. PMID 25271314.